Oncolytics rises as it schedules FDA talks on anal cancer drug

Shares of biotech firm Oncolytics Biotech ONCY.O rise 2% to $0.97

Co says it will meet the FDA on April 16 to discuss a possible approval path for its experimental anal cancer drug pelareorep

This rare cancer starts in anal canal and few options exist once standard treatments fail

Co says it plans to propose a single‑arm study combining pelareorep with a type of cancer immunotherapy in patients who have no approved alternatives

Earlier study showed about a 30% tumor response rate lasting around 17 months, compared with 10%–14% and about 9.5 months for existing options, co says

Including session's move, stock up ~12% YTD